MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ
2.910
+0.120
+4.30%
After Hours: 2.910 0 0.00% 19:30 10/09 EDT
OPEN
2.830
PREV CLOSE
2.790
HIGH
2.965
LOW
2.815
VOLUME
541.23K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
2.700
MARKET CAP
288.52M
P/E (TTM)
-2.3460
1D
5D
1M
3M
1Y
5Y
1D
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
Barchart · 1d ago
X4 Pharmaceuticals Secures New $150 Million Term Loan
TipRanks · 1d ago
X4 Strengthens Cash Position Ahead Of Key Phase 3 Milestones
NASDAQ · 2d ago
X4 Pharmaceuticals secures up to $150M debt facility
Seeking Alpha · 2d ago
Press Release: X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
Dow Jones · 2d ago
Weekly Report: what happened at XFOR last week (0928-1002)?
Weekly Report · 5d ago
Press Release: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 10/01 20:30
Weekly Report: what happened at XFOR last week (0921-0925)?
Weekly Report · 09/28 09:56
More
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Webull offers X4 Pharmaceuticals Inc stock information, including NASDAQ: XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XFOR stock methods without spending real money on the virtual paper trading platform.